Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000634
Chunk: 29

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 29
---
 shares of Common Stock, subject to certain beneficial ownership limitations.

As consideration in the Merger, Dr. Kalayoglu, together with his affiliated entities (including the Trust), collectively received an aggregate of 118,714 shares of Common Stock and 203,892.376 shares of Series A Preferred Stock.

In addition to the Securities Purchase Agreement, in connection with the Transactions, we entered into the 2023 RRA with the Selling Stockholders.

April 2022 Offering

In April 2022, we completed an SEC-registered securities offering pursuant to which we issued and sold an aggregate of 914,285 shares of our Common Stock and accompanying warrants to purchase 685,712 shares of our Common Stock, at a combined purchase price of $42.30, for aggregate net proceeds to us of approximately $36.9 million. In this offering, TAS purchased 222,720 shares of Common Stock and warrants to purchase 167,040 shares of Common Stock for a total purchase price of approximately $9.4 million.

Support Agreements

In connection with the execution of the Merger Agreement, we and Old Cartesian entered into the Support Agreements with certain of our pre-Merger officers, directors and stockholders, including Dr. Springer and TAS. Pursuant to the Support Agreements, among other things, each of our pre-Merger stockholder parties thereto agreed to vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the proposals we submitted for stockholder approval at our March 2024 special meeting of stockholders.

Indemnification Agreements

We have entered into indemnification agreements with each of our directors and executive officers, including Drs. Springer and Kalayoglu. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by a director or an executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of such person’s services as a director or executive officer.

<div align='center'>21</div>

TABLE OF CONTENTS

PLAN OF DISTRIBUTION We are registering resales of Resale Shares to permit the sale, transfer or other disposition of the Resale Shares by the Selling Stockholders or their donees, pledgees, transfere